Hematology

The warning has prompted new CDC recommendations for prevention and molecular diagnostic testing.

The combination also produced a 78.6% complete response rate in heavily pretreated patients with R/R mantle cell lymphoma following BTK inhibitor therapy.

Phase 3 MajesTEC-9 findings show teclistamab monotherapy significantly improves progression-free survival and overall survival compared with PVd or Kd.

A first-in-class RNA degrader targeting MYC mRNA showed preclinical antimyeloma activity, offering a potential new strategy for targeting a historically difficult-to-drug driver of multiple myeloma.

Patients with nodal TFHL had a 5.3% 5-year incidence of subsequent myeloid neoplasms, with shared TET2 mutations supporting divergent evolution from underlying clonal hematopoiesis.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses how pharmacists can layer mediator-symptom management with cytoreductive or targeted therapy in systemic mastocytosis (SM) and interdisciplinary communication.

An investigational KRAS-targeted peptide vaccine generated durable immune responses and demonstrated early potential to intercept pancreatic cancer development in high-risk patients.

Revumenib and ziftomenib in NPM1-mutated AML: practical guidance on differentiation syndrome, QTc monitoring, and drug interactions.

Radiopharmaceuticals force oncology pharmacists to master safety, timing, waste, and costs—see how departments build radioactive therapy workflows.

July 2026 brought major hematology advances in gene therapy, transplantation, targeted treatments, and bleeding disorder care, alongside notable clinical trial setbacks.

Subcutaneous isatuximab could compete with daratumumab in multiple myeloma by combining a hands-free, on-body delivery system with potential advantages in workflow, patient experience, and mechanisms of action.

Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naive and –treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Ravulizumab-cwvz did not significantly improve 26-week event-free survival in adults and adolescents with HSCT-associated thrombotic microangiopathy.

Cassandra Perkey, PharmD, BCOP, explains the operational, staffing, infrastructure, safety, and pharmacist-led requirements for successfully delivering CAR T-cell therapy in a community oncology setting.

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, discussed the patient selection, standardized workflows, toxicity management, payer coordination, and caregiver education needed to safely move bispecific step-up dosing into the outpatient setting.

In an interview with Pharmacy Times, Nicole McMullin, regional clinical pharmacist at American Oncology Network, discussed AON’s development of an all-outpatient approach to step-up dosing for bispecific T-cell engager therapy in multiple myeloma.

Clinicians can mitigate anemia during cancer treatment by reducing the dose, switching to alternate-day dosing, or providing growth factor support.

The FDA approval gives patients with multiple myeloma a second subcutaneous anti-CD38 option alongside daratumumab.

The FDA expanded Wilate's approval for routine prophylaxis to reduce bleeding episodes in children younger than 6 years with von Willebrand disease, supported by phase 3 WIL-33 data showing low annualized bleeding rates and favorable tolerability.

Tregzi is indicated in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen for hematopoietic and immunologic reconstitution and to improve chronic graft-vs-host disease–free survival.

Findings from EPCORE DLBCL-4 show that fixed-duration epcoritamab plus lenalidomide significantly improved progression-free survival (PFS) vs R-GemOx in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

AML and menin inhibitors transform acute myeloid leukemia treatment: FDA-approved choices, MEN1 protein target, and bedside toxicity monitoring.

A combination regimen of azacitidine, venetoclax, and gilteritinib shows encouraging benefits in patients with newly diagnosed FLT3-mutated AML who were ineligible for intensive chemotherapy.

Single-cell findings presented at EHA 2026 identify B cells as potential drivers of immune dysregulation in acquired hemophilia A.

Oncology pharmacists decode 2026 ASCO/EHA breakthroughs, from breast cancer to myeloma, highlighting real-world steps for safer, faster care.